The Motley Fool
15 Aug 2026, 18:00 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Eli Lilly is developing retatrutide, a next-generation medicine that phase 3 data suggests is more effective than Zepbound and treats obesity-related complications like sleep apnea and osteoarthritis pain. — A more effective drug with broader indications expands the addressable market and strengthens the company's competitive moat against rivals.
+0.60Eli Lilly launched Foundayo, an oral anti-obesity medicine, with over 80% of prescriptions coming from patients who had never used GLP-1s before. — Expanding the delivery method to oral pills captures a new patient demographic (needle-averse), driving incremental revenue growth.
+0.40The company is developing eloralintide, a non-GLP-1 drug targeting the amylin hormone to provide similar weight-loss efficacy with better gastrointestinal tolerability. — Reducing side effects lowers patient attrition and provides a viable alternative for those who cannot tolerate current GLP-1 therapies.
+0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company shows strong growth in weight-loss drugs and a robust pipeline of next-gen medicines to maintain market share.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
PRNewsWire
3h ago
